期刊
DRUG DISCOVERY TODAY
卷 21, 期 1, 页码 180-189出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2015.10.012
关键词
-
资金
- ETH Zurich
- Swiss National Science Foundation
- KTI MedTech Project
- ERC Advanced Grant (ZAUBERKUGEL)
Antibody-cytokine fusion proteins, often referred to as immunocytokines, represent a novel class of biopharmaceutical agents that combine the disease-homing activity of certain antibodies with the immunomodulatory properties of cytokine payloads. Originally, immunocytokines were mainly developed for cancer therapy applications. More recently, however, the use of anti-inflammatory cytokines for the treatment of chronic inflammatory conditions and to treat autoimmune diseases has been considered. This review analyzes basic principles in the design of immunocytokines and describes the most advanced products in preclinical and clinical development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据